Head-to-head evidence
Ensartinib vs Neladalkib NVL-655
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: ALK · full Non-Small Cell Lung Cancer pipeline
Ensartinib
Marketed by Xcovery Holdings
NCT01625234 · Phase 1/2 · completed
This was a non-randomized, open-label, single-arm study with 131 participants and no placebo or active comparator. Its primary endpoint was the maximum tolerated dose, a dose-finding safety outcome rather than a clinical efficacy endpoint, so the findings provide limited controlled evidence for ensartinib’s treatment benefit.
Next expected readout: February 2027 · NCT05241028 (registry estimate)
Neladalkib NVL-655
Developed by Nuvalent, Inc. and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2029 · NCT06765109 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ensartinib's landscape · Neladalkib NVL-655's landscape